Löfling L, et al. - Given that antimuscarinic medication is the main pharmacological group used in the treatment of overactive bladder (OAB), researchers studied the relationship between exposure to antimuscarinic medication and the risk of lung cancer and colon cancer. Between July 1, 2006, and December 31, 2012, people in Sweden who first completed an antimuscarinic medication prescription used to treat OAB were identified and classified as exposed. A total of 164,000 exposed and 1,446,472 unexposed persons were included in this analysis. The investigators noted an inverse association between exposure to antimuscarinic medications used in the treatment of OAB and a diagnosis of colon cancer or lung cancer, which was consistent with the findings from preclinical studies.